Berobenatide vs VCT220

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: GLP-1 receptor · full Obesity pipeline

Berobenatide

Developed by Pfizer

Phase 3 in Obesitypeptide
Partial signal

NCT06712836 · Phase 2 · completed

The study randomized 239 participants to MET097 or placebo and used quadruple masking of participants, care providers, investigators, and outcome assessors. Its primary endpoint was the clinical outcome of body-weight change at Week 28. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: January 2027 · NCT07508241 (registry estimate)

Reported efficacy

Percent change from baseline in body weight at Week 28 (Baseline (Week 0) through Week 28 (Day 197)): Percent change in body weight at week 28 (Part A): berobenatide 0.4, 0.6, 0.9 and 1.2 mg weekly -6.41%, -8.36%, -11.29% and -12.45% vs placebo +1.67%; placebo-adjusted -8.09% to -14.13%, all p<0.0001 (CT.gov posted results). (met)

Result source: NCT06712836

VCT220

Developed by Ji Xing Pharmaceuticals (CORXEL) and partners

Phase 3 in Obesitysmall molecule
Partial signal

NCT06939296 · Phase 3 · completed

This was a randomized, double-blind Phase 3 trial with 840 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-05-18. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.

Next expected readout: March 2027 · NCT07652047 (registry estimate)

Reported efficacy

Percentage change from baseline in body weight (From baseline to week 34); The proportion of subjects with a body weight reduction ≥5% from baseline (From baseline to week 34): Primary endpoint met: 52-week weight loss about 12.2% and 12.4% vs 1.3% with placebo (2026-05-18). (met)

Result source: NCT06939296

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBerobenatideVCT220
Body weight, % change—Trial running · NCT07311850—Not posted · NCT06939296
Weight loss of 5% or more—Trial running · NCT07311850—Not posted · NCT06939296
Weight loss of 10% or more—Trial running · NCT07311850—Not posted · NCT06939296
Waist circumference, change (cm)—Trial running · NCT07311850—Not posted · NCT06939296

Body weight, % change

Berobenatide
—Trial running · NCT07311850
VCT220
—Not posted · NCT06939296

Weight loss of 5% or more

Berobenatide
—Trial running · NCT07311850
VCT220
—Not posted · NCT06939296

Weight loss of 10% or more

Berobenatide
—Trial running · NCT07311850
VCT220
—Not posted · NCT06939296

Waist circumference, change (cm)

Berobenatide
—Trial running · NCT07311850
VCT220
—Not posted · NCT06939296
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Berobenatide
Percent change in body weight at week 28 (Part A): berobenatide 0.4, 0.6, 0.9 and 1.2 mg weekly -6.41%, -8.36%, -11.29% and -12.45% vs placebo +1.67%; placebo-adjusted -8.09% to -14.13%, all p<0.0001 (CT.gov posted results). NCT06712836 · Phase 2 · design grade: moderate · reviewed ClinicalTrials.gov result
VCT220
Phase 2 trial, explicitly named as NCT07011797: primary endpoints met, up to 11.5% weight loss at 36 weeks with CX11 (oral GLP-1 receptor agonist), ongoing weight loss without plateau; gastrointestinal AEs the most common safety finding. NCT07011797 · Phase 2 · design grade: strong · publication or press release
Primary endpoint met: 52-week weight loss about 12.2% and 12.4% vs 1.3% with placebo (2026-05-18). NCT06939296 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result
Primary endpoint (mean % body weight change, baseline to week 16): -5.8% to -9.7% across VCT220 dose cohorts vs -1.6% placebo; 9.7% and 9.4% decrease at 160 mg fast/slow titration (p<=0.001) NCT06569355 · Phase 2 · design grade: strong · publication or press release

Type 2 Diabetes

Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline

Berobenatide

Developed by Pfizer

Phase 3 in Type 2 Diabetespeptide
Partial signal

NCT06897202 · Phase 2 · completed

The trial randomly assigned 133 participants to MET097 or placebo and was double-blinded, with percent change in body weight as the primary clinical endpoint. However, because no primary efficacy results are available, it is not possible to determine whether the endpoint was met.

Figures from conference coverage of the ADA 2026 presentation; weight change is from baseline, not placebo-adjusted, and no significance testing was reported for the weight endpoint. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: October 2027 · NCT07400653 (registry estimate)

Reported efficacy

Percent change from baseline in body weight at Week 28 (Day 197) (Baseline (Week 0) through Week 28 (Day 197)): Dose-dependent body weight decrease up to 10.2% and HbA1c reduction up to 2.2% at the highest weekly dose

Result source: NCT06897202

VCT220

Developed by Ji Xing Pharmaceuticals (CORXEL) and partners

Phase 2 in Type 2 Diabetessmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: April 2027 · NCT07340320 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBerobenatideVCT220
HbA1c, change—Trial running · NCT07400653—Not reported
Body weight, change (kg)—Trial running · NCT07400653—Not reported
HbA1c below 7%—Trial running · NCT07400653—Not reported
Fasting plasma glucose, change—Trial running · NCT07400653—Not reported
3-point MACE (% with event)—Trial running · NCT07400653—Not reported

HbA1c, change

Berobenatide
—Trial running · NCT07400653
VCT220
—Not reported

Body weight, change (kg)

Berobenatide
—Trial running · NCT07400653
VCT220
—Not reported

HbA1c below 7%

Berobenatide
—Trial running · NCT07400653
VCT220
—Not reported

Fasting plasma glucose, change

Berobenatide
—Trial running · NCT07400653
VCT220
—Not reported

3-point MACE (% with event)

Berobenatide
—Trial running · NCT07400653
VCT220
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

VCT220: no structured comparison results are available for Type 2 Diabetes.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Berobenatide
Dose-dependent body weight decrease up to 10.2% and HbA1c reduction up to 2.2% at the highest weekly dose NCT06897202 · Phase 2 · design grade: moderate · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Berobenatide's landscape · VCT220's landscape